Selected research
Industry Research
Insomnia Medication Industry Research Report 2026
Market perspective
The global Insomnia Medication market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Insomnia Medication is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Insomnia Medication is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Insomnia Medication is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Insomnia Medication include Takeda, Eisai, Sanofi, Johnson & Johnson, Merck, Pfizer, Vanda Pharmaceuticals, Somnus Therapeutics and SkyePharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Insomnia Medication market in terms of revenue (US$ million) and, where applicable, sales volume (W Pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Insomnia Medication Market by Company
Takeda
Eisai
Sanofi
Johnson & Johnson
Merck
Pfizer
Vanda Pharmaceuticals
Somnus Therapeutics
SkyePharma
Purdue Pharma
Pernix Therapeutics
Paratek Pharmaceuticals
Neurim
Minerva Neurosciences
Meda
Flynn Pharma
ECR Pharmaceuticals (Valeant)
Dainippon Sumitomo
Astellas
Insomnia Medication Segment by Type
Benzodiazepine Receptor Agonists
Nonbenzodiazepine Receptor Agonists
The Selective Melatonin Receptor Agonist Ramelteon
Sedating Antidepressants
Insomnia Medication Segment by Application
Adults
Kids
Insomnia Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Insomnia Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Insomnia Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Insomnia Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Insomnia Medication manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Insomnia Medication by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Insomnia Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Benzodiazepine Receptor Agonists
- Nonbenzodiazepine Receptor Agonists
- The Selective Melatonin Receptor Agonist Ramelteon
- Sedating Antidepressants
Applications
- Adults
- Kids
Companies covered
- Takeda
- Eisai
- Sanofi
- Johnson & Johnson
- Merck
- Pfizer
- Vanda Pharmaceuticals
- Somnus Therapeutics
- SkyePharma
- Purdue Pharma
- Pernix Therapeutics
- Paratek Pharmaceuticals
- Neurim
- Minerva Neurosciences
- Meda
- Flynn Pharma
- ECR Pharmaceuticals (Valeant)
- Dainippon Sumitomo
- Astellas
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Insomnia Medication Market Size (2021-2032)
- 2.2.2 Global Insomnia Medication Sales (2021-2032)
- 2.2.3 Global Insomnia Medication Market Average Price (2021-2032)
- 2.3 Insomnia Medication by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Benzodiazepine Receptor Agonists
- 2.3.3 Nonbenzodiazepine Receptor Agonists
- 2.3.4 The Selective Melatonin Receptor Agonist Ramelteon
- 2.3.5 Sedating Antidepressants
- 2.4 Insomnia Medication by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Adults
- 2.4.3 Kids
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Insomnia Medication Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Insomnia Medication Sales (W Pcs) of Manufacturers (2021-2026)
- 3.3 Global Insomnia Medication Revenue of Manufacturers (2021-2026)
- 3.4 Global Insomnia Medication Average Price by Manufacturers (2021-2026)
- 3.5 Global Insomnia Medication Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Insomnia Medication, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Insomnia Medication, Product Type & Application
- 3.8 Global Manufacturers of Insomnia Medication, Established Date
- 3.9 Global Insomnia Medication Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Takeda
- 4.1.1 Takeda Company Information
- 4.1.2 Takeda Business Overview
- 4.1.3 Takeda Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Takeda Insomnia Medication Product Portfolio
- 4.1.5 Takeda Recent Developments
- 4.2 Eisai
- 4.2.1 Eisai Company Information
- 4.2.2 Eisai Business Overview
- 4.2.3 Eisai Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eisai Insomnia Medication Product Portfolio
- 4.2.5 Eisai Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Insomnia Medication Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Insomnia Medication Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Merck
- 4.5.1 Merck Company Information
- 4.5.2 Merck Business Overview
- 4.5.3 Merck Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Merck Insomnia Medication Product Portfolio
- 4.5.5 Merck Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Insomnia Medication Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Vanda Pharmaceuticals
- 4.7.1 Vanda Pharmaceuticals Company Information
- 4.7.2 Vanda Pharmaceuticals Business Overview
- 4.7.3 Vanda Pharmaceuticals Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Vanda Pharmaceuticals Insomnia Medication Product Portfolio
- 4.7.5 Vanda Pharmaceuticals Recent Developments
- 4.8 Somnus Therapeutics
- 4.8.1 Somnus Therapeutics Company Information
- 4.8.2 Somnus Therapeutics Business Overview
- 4.8.3 Somnus Therapeutics Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Somnus Therapeutics Insomnia Medication Product Portfolio
- 4.8.5 Somnus Therapeutics Recent Developments
- 4.9 SkyePharma
- 4.9.1 SkyePharma Company Information
- 4.9.2 SkyePharma Business Overview
- 4.9.3 SkyePharma Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 SkyePharma Insomnia Medication Product Portfolio
- 4.9.5 SkyePharma Recent Developments
- 4.10 Purdue Pharma
- 4.10.1 Purdue Pharma Company Information
- 4.10.2 Purdue Pharma Business Overview
- 4.10.3 Purdue Pharma Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Purdue Pharma Insomnia Medication Product Portfolio
- 4.10.5 Purdue Pharma Recent Developments
- 4.11 Pernix Therapeutics
- 4.11.1 Pernix Therapeutics Company Information
- 4.11.2 Pernix Therapeutics Business Overview
- 4.11.3 Pernix Therapeutics Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Pernix Therapeutics Insomnia Medication Product Portfolio
- 4.11.5 Pernix Therapeutics Recent Developments
- 4.12 Paratek Pharmaceuticals
- 4.12.1 Paratek Pharmaceuticals Company Information
- 4.12.2 Paratek Pharmaceuticals Business Overview
- 4.12.3 Paratek Pharmaceuticals Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Paratek Pharmaceuticals Insomnia Medication Product Portfolio
- 4.12.5 Paratek Pharmaceuticals Recent Developments
- 4.13 Neurim
- 4.13.1 Neurim Company Information
- 4.13.2 Neurim Business Overview
- 4.13.3 Neurim Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Neurim Insomnia Medication Product Portfolio
- 4.13.5 Neurim Recent Developments
- 4.14 Minerva Neurosciences
- 4.14.1 Minerva Neurosciences Company Information
- 4.14.2 Minerva Neurosciences Business Overview
- 4.14.3 Minerva Neurosciences Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Minerva Neurosciences Insomnia Medication Product Portfolio
- 4.14.5 Minerva Neurosciences Recent Developments
- 4.15 Meda
- 4.15.1 Meda Company Information
- 4.15.2 Meda Business Overview
- 4.15.3 Meda Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Meda Insomnia Medication Product Portfolio
- 4.15.5 Meda Recent Developments
- 4.16 Flynn Pharma
- 4.16.1 Flynn Pharma Company Information
- 4.16.2 Flynn Pharma Business Overview
- 4.16.3 Flynn Pharma Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Flynn Pharma Insomnia Medication Product Portfolio
- 4.16.5 Flynn Pharma Recent Developments
- 4.17 ECR Pharmaceuticals (Valeant)
- 4.17.1 ECR Pharmaceuticals (Valeant) Company Information
- 4.17.2 ECR Pharmaceuticals (Valeant) Business Overview
- 4.17.3 ECR Pharmaceuticals (Valeant) Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 ECR Pharmaceuticals (Valeant) Insomnia Medication Product Portfolio
- 4.17.5 ECR Pharmaceuticals (Valeant) Recent Developments
- 4.18 Dainippon Sumitomo
- 4.18.1 Dainippon Sumitomo Company Information
- 4.18.2 Dainippon Sumitomo Business Overview
- 4.18.3 Dainippon Sumitomo Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Dainippon Sumitomo Insomnia Medication Product Portfolio
- 4.18.5 Dainippon Sumitomo Recent Developments
- 4.19 Astellas
- 4.19.1 Astellas Company Information
- 4.19.2 Astellas Business Overview
- 4.19.3 Astellas Insomnia Medication Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Astellas Insomnia Medication Product Portfolio
- 4.19.5 Astellas Recent Developments
5 Global Insomnia Medication Market Scenario by Region
- 5.1 Global Insomnia Medication Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Insomnia Medication Sales by Region: 2021-2032
- 5.2.1 Global Insomnia Medication Sales by Region: 2021-2026
- 5.2.2 Global Insomnia Medication Sales by Region: 2027-2032
- 5.3 Global Insomnia Medication Revenue by Region: 2021-2032
- 5.3.1 Global Insomnia Medication Revenue by Region: 2021-2026
- 5.3.2 Global Insomnia Medication Revenue by Region: 2027-2032
- 5.4 North America Insomnia Medication Market Facts & Figures by Country
- 5.4.1 North America Insomnia Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Insomnia Medication Sales by Country (2021-2032)
- 5.4.3 North America Insomnia Medication Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Insomnia Medication Market Facts & Figures by Country
- 5.5.1 Europe Insomnia Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Insomnia Medication Sales by Country (2021-2032)
- 5.5.3 Europe Insomnia Medication Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Insomnia Medication Market Facts & Figures by Country
- 5.6.1 Asia Pacific Insomnia Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Insomnia Medication Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Insomnia Medication Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Insomnia Medication Market Facts & Figures by Country
- 5.7.1 South America Insomnia Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Insomnia Medication Sales by Country (2021-2032)
- 5.7.3 South America Insomnia Medication Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Insomnia Medication Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Insomnia Medication Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Insomnia Medication Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Insomnia Medication Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Insomnia Medication Sales by Type (2021-2032)
- 6.1.1 Global Insomnia Medication Sales by Type (2021-2032) & (W Pcs)
- 6.1.2 Global Insomnia Medication Sales Market Share by Type (2021-2032)
- 6.2 Global Insomnia Medication Revenue by Type (2021-2032)
- 6.2.1 Global Insomnia Medication Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Insomnia Medication Revenue Market Share by Type (2021-2032)
- 6.3 Global Insomnia Medication Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Insomnia Medication Sales by Application (2021-2032)
- 7.1.1 Global Insomnia Medication Sales by Application (2021-2032) & (W Pcs)
- 7.1.2 Global Insomnia Medication Sales Market Share by Application (2021-2032)
- 7.2 Global Insomnia Medication Revenue by Application (2021-2032)
- 7.2.1 Global Insomnia Medication Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Insomnia Medication Revenue Market Share by Application (2021-2032)
- 7.3 Global Insomnia Medication Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Insomnia Medication Value Chain Analysis
- 8.1.1 Insomnia Medication Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Insomnia Medication Production Mode & Process
- 8.2 Insomnia Medication Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Insomnia Medication Distributors
- 8.2.3 Insomnia Medication Customers
9 Global Insomnia Medication Analyzing Market Dynamics
- 9.1 Insomnia Medication Industry Trends
- 9.2 Insomnia Medication Industry Drivers
- 9.3 Insomnia Medication Industry Opportunities and Challenges
- 9.4 Insomnia Medication Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst